Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 13/20 | 0.58 |
| ▸ | HSD17B1 | P14061 | 12/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215959 | 0.87 | HSD17B2 (0.60) | HSD17B2HSD17B1L3MBTL1HTR1AHTR2A | |
| SCHEMBL3227796 | 0.86 | HSD17B2 (0.58) | HSD17B2HSD17B1L3MBTL1HTR1AHTR2A | |
| SCHEMBL12495722 | 0.78 | HSD17B2 (0.59) | HSD17B2HSD17B1MTNR1AMTNR1BGPBAR1 | |
| SCHEMBL6796131 | 0.77 | HSD17B2 (0.91) | HSD17B2HSD17B1MTNR1AMTNR1B | |
| SCHEMBL20264517 | 0.76 | HSD17B2 (0.61) | HSD17B2HSD17B1MTNR1AMTNR1B | |
| SCHEMBL11027897 | 0.76 | HSD17B2 (0.61) | HSD17B2HSD17B1MTNR1AMTNR1B | |
| SCHEMBL22887209 | 0.76 | HSD17B2 (0.55) | HSD17B2HSD17B1L3MBTL1 | |
| Dimethyl Phthalate SCHEMBL28386688 | 0.75 | TSHR (0.59) | L3MBTL1 | |
| SCHEMBL10940468 | 0.74 | HSD17B2 (0.60) | HSD17B2HSD17B1MTNR1AMTNR1B | |
| SCHEMBL9956630 | 0.74 | HSD17B2 (0.60) | HSD17B2HSD17B1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | GENESTE HERVE | 2010-02-25 | — | — | US | disclosed |
| US-20040077638-A1 | Novel integrin receptor antagonists | BASF AKTIENGESELLCHAFT (DE) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | ITGB3, ITGAL, ITGB4 | HSD17B2 4746/4885HSD17B1 4796/4885L3MBTL1 4126/4885 |
| US-20040077638-A1 | Novel integrin receptor antagonists | ITGB3, ITGAV, ITGA2B | HSD17B2 4828/4885HSD17B1 4823/4885L3MBTL1 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.